Dr. Tefferi on Recent Ruxolitinib Combination Trials for Myelofibrosis

In this episode of the “Blood Cancer Talks” podcast, Raj Chakraborty, MD; and Ashwin Kishtagari, MD, host Ayalew Tefferi, MD, an expert on myeloproliferative neoplasms from the Mayo Clinic Rochester. Dr. Tefferi shared his impressions of recent clinical trials in combination therapy for myelofibrosis.

The trio discussed the TRANSFORM-1 and MANIFEST-2 trials, in which ruxolitinib was combined with navitoclax and pelabresib, respectively. Dr. Tefferi gave his assessment of the trial designs and results and described how he would manage patients in similar clinical situations in his own practice.